United States – October 27, 2026 -- Solid Biosciences has dosed 40 participants with its Duchenne gene therapy SGT-003 and reported positive interim safety and biomarker data from the ongoing Phase 1/2 INSPIRE DUCHENNE trial. The company presented the update at the 2026 MDA Clinical & Scientific Conference.

United States – October 27, 2026 -- Solid Biosciences has expanded its INSPIRE DUCHENNE gene therapy trial to 43 participants and now accepts children aged 4 to under 12, up from the previous range of 4 to under 8.

Three participants dosed with no serious adverse events

INSPIRE DUCHENNE is a first-in-human, multicenter, Phase 1/2 open-label study. It tests the safety, tolerability and efficacy of a single intravenous infusion of SGT-003, a next-generation AAV gene therapy candidate, in ambulant boys with Duchenne.

United States – October 27, 2026 -- Families affected by Duchenne muscular dystrophy have early data on SGT-003, an investigational gene therapy from Solid Biosciences: 90 days after dosing, three boys showed average microdystrophin expression of 110%.

Global – October 27, 2026 -- Fifty-three boys with Duchenne muscular dystrophy have now received the investigational gene therapy SGT-003, and a Phase 3 trial is already enrolling patients in Australia and Canada. Solid Biosciences shared the update in a letter to the Duchenne community as the annual Parent Project Muscular Dystrophy (PPMD) conference got under way.

United States – October 27, 2026 -- Solid Biosciences has dosed 33 children aged 1 to 10 with its investigational gene therapy SGT-003 for Duchenne muscular dystrophy, and a Phase 3 trial has enrolled its first patient.

United States – October 27, 2026 -- Cannabis sold in legal-sale states in 2023 contains 25-90% THC, compared with roughly 2-4% before 1990, so parents who tried it in their youth may be thinking of a very different drug. Mothers Against Drunk Driving (MADD) is urging parents to update their conversations with teens through its Power of Parents program.

New York – October 21, 2026 -- RVO Health's Script Portability technology lets consumers see their pharmacy options, with cost and convenience details, before a prescription is sent. The company has now received its third U.S. patent covering the capability.

A third patent joins two earlier ones in the Siegel family

The U.S. Patent and Trademark Office granted U.S. Patent No. 12,580,060 B2. The earlier patents in the same family are No. 11,651,843 and No. 12,119,098.

Orange County – October 20, 2026 -- Older LGBTQ+ adults in Orange County can get routine primary care at the Radiant Health Centers LGBTQ+ clinic, which offers preventive screenings and chronic disease management in a stigma-free setting.

Orange County – October 20, 2026 -- Routine checkups, screenings and wellness exams can help LGBTQ+ adults stay independent as they age, according to Radiant Health Centers, an LGBTQ+ medical clinic serving Orange County.

Irvine – October 20, 2026 -- Patients heading into a first primary care visit in Orange County can prepare with three steps: gather health records, write down questions and know what the appointment includes, according to Radiant Health Centers.

The clinic has served LGBTQ+ patients in Irvine, Santa Ana and across Orange County for more than 40 years. It describes its primary care as inclusive and judgment-free, with patients able to discuss their health openly.